KCRS26 Presentations & Videos
Program content is now LIVE!
The program slide presentations are available now and can be viewed by clicking the icon to the left of the title. Each video is the full session length; to jump to a particular presentation, note the timestamp in red beneath the speaker’s name.
DAY ONE PRESENTATIONS
DAY TWO PRESENTATIONS
Thursday, July 23rd
Welcome & IntroductionsÂ
Bryan Lewis, KidneyCAN CEO
Click the icon next to the presentation to view slides
Keynote Address
Membrane Synthesis as a Potential Achilles’ Heel of Renal Carcinoma
Craig Thompson, Memorial Sloan Kettering Cancer Center
SESSION ONE:
Current Role of Artificial Intelligence in Kidney Cancer
Click the icon next to the presentation to view slides
Overview of Artificial Intelligence in Cancer Genomics
Sylvan Baca, Dana-Farber Cancer Institute
(Video presentation begins at 0:57)
Incorporating Artificial Intelligence into Pathology
Julie Stein Deutsch, Johns Hopkins Medicine
(Video presentation begins at 10:05)
The Role of Radiomics and Artificial Intelligence in Kidney Cancer
Andrew Smith, St. Jude Children’s Research Hospital
(Video presentation begins at 18:10)
Trial Discovery for Every Cancer Patient
Hari Kasi, Almara, Inc.
(Video presentation begins at 27:40)
SESSION TWO:
Sustaining Momentum in Kidney Cancer Research in an Era of Reduced Federal Funding
Click the icon next to the presentation to view slides
Moderator Introduction
Michael Atkins Georgetown-Lombardi Comprehensive Cancer Center
(Video presentation begins at 0:03)
Academy of Kidney Cancer Investigators Impact
Abhishek Chakraborty, Cleveland Clinic
(Video presentation begins at 08:55)
Kidney Cancer Research Consortium Impact
Eric Jonasch, MD Anderson Cancer Center
(Video presentation begins at 14:45)
UT Southwestern Medical Center SPORE Impact
James Brugarolas, UT Southwestern Medical Center
(Video presentation begins at 19:50)
Dana-Farber/Harvard Cancer Center SPORE Impact
David McDermott, Beth Israel Deaconess Medical Center
(Video presentation begins at 26:05)
Moderated Panel Discussion
All presenters plus Toni Choueiri, Dana-Farber Cancer Center
(Video presentation begins at 31:50)
FIRESIDE CHAT WITH ARIE BELLDEGRUN
Innovation, Investment, and the Future of Kidney Cancer Research
In conversation with
Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center, & Toni Choueiri, Dana-Farber Cancer Institute
SESSION THREE:
Best of KCRS – Plenary Abstract Session
Click the icon next to the presentation to view slides
Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022
Thomas Powles, Barts Cancer Center
(Video presentation begins at 0:58)
Relationships Between Plasma KIM-1 Levels, Peripheral Immune Profiles and Disease-Free Survival Outcomes in the TransRAMPART Study
James Jones, University of Cambridge
(Video presentation begins at 23:11)
Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)
Rana McKay, University of California, San Diego
(Video presentation begins at 41:47)
SESSION FOUR:
Oral Abstract Presentations
Click the icon next to the presentation to view slides
Baseline and Early On‑Treatment Plasma Kidney Injury Molecule-1 (KIM‑1) Levels Are Associated with Outcomes in Advanced Renal Cell Carcinoma (aRCC)
Wenxin Xu, Dana-Farber Cancer Institute
(Video presentation begins at 0:53)
Stereotactic Body Radiation Therapy Enriches Mediators of Humoral Immune Activity in Metastatic Renal Cell Carcinoma
Nicholas Salgia, Roswell Park Comprehensive Cancer Center
(Video presentation begins at 8:33)
Antitumor Activity of 177Lu-PSMA-617 in PSMA-Positive Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Results from a Phase 2 Trial (LASER)
Praful Ravi, Dana-Farber Cancer Institute
(Video presentation begins at 16:32)
Mitochondrial DNA Mutations Phenocopy VHL Loss to Drive Non-Clear Cell RCC
Ziad Bakouny, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 42:56)
Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)
Rishabh Rout, Yale School of Medicine
(Video presentation begins at 53:07)
CD8+ T Cells and Clinical Outcomes from the CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) Trial
Karie Runcie, Columbia University Herbert Irving Comprehensive Cancer Center
(Video presentation begins at 1:00:48)
Friday, July 24th
Founding Partner Presentation
Exelixis-Driven Progress in Renal Cell Carcinoma: Evidence Today and the Pipeline Ahead
Tasha Hall, Exelixis
SESSION FIVE:
Next-Generation Immunotherapy: Emerging Science and New Approaches
Click the icon next to the presentation to view slides
Targeting the Microbiome in Cancer Immunotherapies
Bertrand Routy, University of Montreal
(Video presentation begins at 1:12)
Ivonescimab: A Novel First-in-Class PD-1 x VEGF Bispecific Antibody
Fiona An, Summit Therapeutics
(Video presentation begins at 24:40)
The Cancer Dark Proteome: A Rich Source of Novel Tumor Antigens
Will Freed-Pastor, Dana-Farber Cancer Institute
(Video presentation begins at 44:47)
AI Protein Design
John Connolly, Parker Institute for Cancer Immunotherapy
(Video presentation begins at 1:04:20)
SESSION SIX:
Shaping the Next Standard of Care for RCC Brain Metastases
Click the icon next to the presentation to view slides
Code to Clinic: Translating Single-Cell, Spatial Genomics, and ML/AI into RCC Brain Metastases Trials and Patient Care
Elshad Hasanov, The Ohio State University
(Video presentation begins at 2:50)
Translational Insights into RCC Brain Metastases
Roy Elias, Johns Hopkins University
(Video presentation begins at 9:45)
Learning from Other Diseases: CNS Success Stories
Harriet Kluger, Yale School of Medicine
(Video presentation begins at 16:13)
Radiosurgery for Brain Metastases: Balancing the Therapeutic Ratio with Novel Systemic Therapies
Raj Singh, Baptist Health South Florida Lynn Cancer Institute
(Video presentation begins at 24:22)
SESSION SEVEN:
Trials in Progress Presentations
Click the icon next to the presentation to view slides
PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415)
Toni Choueiri, Dana-Farber Cancer Institute
(Video presentation begins at 0:26)
A Phase II Study of Total Consolidative Metastasis-and-Primary Directed Therapy for Renal Cell Carcinoma (NCT06770855)
Henry Litt, University of Pennsylvania
(Video presentation begins at 6:24)
Phase II Study of Cemiplimab ± Fianlimab Following SBRT for Oligometastatic Clear-Cell RCC (LAG-BOOST) (NCT07223541)
Abhirami Das, The University of Oklahoma College of Medicine
(Video presentation begins at 10:52)
PRISM: Phase 1b of Retifanlimab and Ruxolitinib in Solid Malignancies Progressing on Prior Checkpoint Inhibition (NCT07219576)
Rana McKay, University of California, San Diego
(Video presentation begins at 15:40)
A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)
Sahil Doshi, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 20:29)
Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626)
Pavlos Msaouel, MD Anderson Cancer Center
(Video presentation begins at 25:40)
SESSION EIGHT:
RCC Breakthroughs: Highlights from AACR, ASCO, ESMO, ASCO GU
Click the icon next to the presentation to view slides
AACR Highlights
Tian Zhang, UT Southwestern Medical Center
(Video presentation begins at 1:09)
ASCO Highlights
Michael Serzan, Dana-Farber Cancer Institute
(Video presentation begins at 12:23)
ESMO Highlights
Laurence Albiges, Gustave Roussy
(Video presentation begins at 31:40)
ASCO GU Highlights
Katy Beckermann, Tennessee Oncology
(Video presentation begins at 50:16)
SESSION NINE:
Rapid Oral Abstract Presentations – Part One
Click the icon next to the presentation to view slides
Outcomes of Patients with Renal Cell Carcinoma Achieving Pathologic Complete or Major Response After Consolidative Nephrectomy Following Immune Checkpoint Inhibitor Therapy
Paulo Siqueira do Amaral, Northwestern University
(Video presentation begins at 0:35)
Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)
Michael Serzan, Dana-Farber Cancer Institute
(Video presentation begins at 5:51)
Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001
Adanma Ayanambakkam, Oklahoma University Health
(Video presentation begins at 9:26)
Molecular and Clinical Characterization of Early-Onset Renal Cell Carcinoma (eoRCC): A Real-World Multi-Omics Analysis
Hedyeh Ebrahimi, Beth Israel Deaconess Medical Center
(Video presentation begins at 12:56)
Evaluation of the Effects of the HIF-α Inhibitor Belzutifan on T-cell–Mediated Cytotoxicity in Renal Cell Carcinoma
Soki Kashima, Yale School of Medicine
(Video presentation begins at 17:47)
SESSION TEN:
Rapid Oral Abstract Presentations – Part Two
Click the icon next to the presentation to view slides
Defining Systemic and Tumor-Intrinsic Biomarkers of Immune Suppression in Renal Cell Carcinoma
Giuliana Mognol, University of California, San Diego
(Video presentation begins at 0:24)
ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy
Hans Hammers, UT Southwestern Medical Center
(Video presentation begins at 5:14)
Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment
Yufei Wang, Dana-Farber Cancer Institute
(Video presentation begins at 10:25)
Prediction of Immune-Related Adverse Events (irAEs) with Hematologic Markers in Patients Receiving First-Line Immune Checkpoint Inhibitor (ICI)-Based Therapy in Metastatic Renal Cell Carcinoma (mRCC)
Rahul Winayak, City of Hope Comprehensive Cancer Center
(Video presentation begins at 15:32)
Dissecting ARNT Expression Patterns in RCC and Association with Outcomes
Yu-Wei Chen, University of California, San Diego
(Video presentation begins at 19:49)
Missed KCRS26? Put a date on your calendar for KCRS27 – July 15th & 16th, 2027